Caliber Imaging & Diagnostics Stock

Caliber Imaging & Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Caliber Imaging & Diagnostics (LCDX) as of Aug 17, 2026 is -4.85 M USD.

EBITDA

-4.85 MUSD

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Caliber Imaging & Diagnostics is 2026 -4.85 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Caliber Imaging & Diagnostics was 2025 - USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Caliber Imaging & Diagnostics Stock analysis

What does Caliber Imaging & Diagnostics do? Caliber Imaging & Diagnostics Inc (CID), founded in 2007, is a medical technology company based in Rochester, New York. CID focuses on the development of optical imaging systems used in the diagnosis of tissue and skin diseases. CID was founded by an experienced leadership team who previously worked at Kodak and focused on developing new imaging technologies. The founders of CID recognized a significant unmet need in the diagnosis of skin diseases, as traditional methods such as biopsies are painful and invasive. Therefore, CID developed a revolutionary technology called VivaScope® that provides a non-invasive, painless method of tissue imaging. This technology allows doctors to make rapid decisions about a patient without having to wait for a biopsy. CID aims to distribute its products in the North American market and expand its presence in other regions such as Europe, Asia, and the Middle East. The company aims to benefit from the growing trends in telemedicine and the widespread use of telemedicine tools and wearables. CID has built trusted relationships with many renowned clinics and medical institutes worldwide to test and validate its VivaScope® technology and increase its industry recognition. CID focuses on providing technologies for the diagnosis of skin diseases and tissues. The VivaScope technology is capable of visualizing tissue structures beneath the skin surface at magnifications of up to 1000x. CID offers three main products: VivaScope® System, VivaScope® 1500, and VivaScope® 3000. The VivaScope® system is an advanced diagnostic system approved by the FDA. It uses advanced optics and VegascanTM software to provide TissueMap™ images, allowing doctors to visualize tissue beneath the skin surface. The VivaScope® 1500 is a portable version of the VivaScope® system used for diagnosing superficial skin diseases such as melanomas, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product, offering higher resolution and better image quality than the VivaScope® system or the VivaScope® 1500. The VivaScope® system has been developed to enable fast, painless, and non-invasive diagnosis of skin diseases. The technology of the VivaScope® system allows doctors to visualize tissue structures and cellular changes beneath the skin surface, which can help reduce the number of painful skin biopsies. VivaScope® 1500 is a handheld version of the VivaScope® system that is easy to transport and provides doctors with a mobile diagnostic capability. This device is ideal for examining superficial skin diseases such as melanomas, basal cell carcinomas, and actinic keratoses. The VivaScope® 3000 is CID's latest product. This advanced diagnostic system offers higher resolution and better image quality than the VivaScope® system and the VivaScope® 1500. The VivaScope® 3000 features the latest technology and can be used for analyzing skin and tissue. In conclusion, CID is an innovative company specializing in the development of optical imaging systems. The company has developed a revolutionary technology called VivaScope, which helps reduce painful skin biopsies and enables doctors to make quick decisions. With a strong presence in the North American market and growing interest in telemedicine, CID has all the prerequisites to become a key player in a rapidly evolving industry. Caliber Imaging & Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Caliber Imaging & Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Caliber Imaging & Diagnostics is -4.85 M USD in 2026.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Caliber Imaging & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Caliber Imaging & Diagnostics historically and in real time.

Access this data via the Eulerpool API

Income Statement — Caliber Imaging & Diagnostics

All Key Metrics — Caliber Imaging & Diagnostics